Entirely, levels of the two biomarkers elevated as it came close to the diagnosis time, but from individual aspect, there existed tremendous diversity in all HCC patients (see Fig. 2, Supplemental Content, which illustrates individual serum level of AFP and PIVKA-II in each HCC patients at validation stage). This evidence concerns the gene AFP and hepatocellular carcinoma.